The RIO study is looking at whether a new type of treatment can keep viral load undetectable without ART. This will involve asking all participants to stop ART for a short time.
The study will measure how long viral load stays undetectable without ART. It will also look at what happens to the HIV virus and immune system in blood samples. When virus becomes detectable in a blood test (viral rebound) you will be asked to re-start your ART.
- Nature publication: antibody therapy controls HIV for months in new clinical trialFindings from a clinical trial led by Rockefeller University scientists as reported by journal Nature highlight anti-HIV antibodies as a […]
- RIO Trial protocol paper published in TrialsWe are pleased to report that the RIO trial protocol has now been published in the peer-reviewed journal Trials. Please […]
- RIO trial updateWe are delighted to note that we are currently recruiting in all 7 clinical sites across London and Brighton and […]
RIO is funded by the Bill & Melinda Gates Foundation. Imperial College London is the Trial Sponsor and the trial is coordinated by Imperial College London, The University of Oxford and The Rockefeller University.